Sorafenib

Current Opinion in Oncology

Volumn 18, Issue 6, 2006, Pages 615-621

  Hahn, Olwen ^a   Stadler, Walter ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Angiogenesis; Renal cell cancer; Sorafenib; Tyrosine kinase inhibitors; Vascular endothelial growth factor

Indexed keywords

ANGIOGENIC FACTOR; BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; CYTOSTATIC AGENT; PACLITAXEL; PHOSPHOTRANSFERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; RAF PROTEIN; SORAFENIB; SUNITINIB; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLEEDING; CANCER SURVIVAL; CLINICAL TRIAL; COUGHING; DIARRHEA; DRUG BLOOD LEVEL; DRUG INDICATION; DRUG MECHANISM; DRUG RESPONSE; DRY SKIN; DYSPNEA; ERYTHEMA; FATIGUE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CANCER; NAUSEA; NEUROPATHY; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RASH; REVIEW; SACCHAROMYCES; SKIN TOXICITY; SPLINTER SUBUNGUAL HEMORRHAGE; STOMATITIS; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CLINICAL TRIALS AS TOPIC; HUMANS; KIDNEY NEOPLASMS; PYRIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 33748912840     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000245316.82391.52     Document Type: Review

References (36)

1. Wilhelm S, Chien DS. BAY 43-9006: preclinical data. Curr Pharm Des 2002; 8:2255-2257.
2. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989; 49:4682-4689.
3. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004; 6:313-319.
4. Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 2005; 23:6771-6790. This review focuses on the Raf pathway, its role in tumorgenesis, and potential as an anticancer target.
5. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-676.
6. Iliopoulos O, Levy AP, Jiang C, et al. Negative regulation of hypoxia inducible genes by the von Hippel Lindau protein. Proc Nat Acad Sci USA 1996; 93:10595-10599.
7. Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000; 2:423-427.
8. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-7109.
9. Karasarides M, Chiloeches A, Hayward R, et al. B-RAF is a therapeutic target in melanoma. Oncogene 2004; 23:6292-6298.
10. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004; 10 (18 Pt 2):6388S-6392S.
11. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23:965-972. This phase I trial reports the disease stabilizing effects of sorafenib at the recommended phase II dosing.
12. Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005; 16:1688-1694.
13. Clark JW, Eder JP, Ryan D, et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005; 11:5472-5480.
14. Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005; 92:1855-1861.
15. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:2505-2512. This phase II data establishes sorafenib's activity in RCC and is also notable for its use of the RDT design for a cytostatic agent.
16. Stadler WM, Ratain MJ. Development of target-based antineoplastic agents. Invest New Drugs 2000; 18:7-16.
17. Freidlin B, Simon R. Evaluation of Randomized Discontinuation Design. J Clin Oncol 2005; 23:5094-5098. This article outlines challenges of clinical trial development of cytostatic agents and reviews the value of RDT design for cytostatic drug development.
18. Rosner GL, Stadler W, Ratain MJ. Randomized Discontinuation Design: Application to Cytostatic Antineoplastic Agents. J Clin Oncol 2002; 20:4478-4484.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216.
20. Escudier B, Szczylik C, Eisen T, et al. Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) [Abstract]. J Clin Oncol 2005; 23 (suppl):4510. First report of phase III data in the sorafenib versus placebo trial in refractory RCC patients; definitively established a progression-free survival favoring sorafenib.
21. Bayer News Server. Updated Overall Survival Analysis Presented on Nexavar Phase III Trial. http://www.news.bayer.com/baynews/baynews.nsf/id/ 48E64FEA44B2F4FCC12571810040218D?Open [Accessed 12 June 2006].
22. Bayer HealthCare. Nexavar Prescribing Information. http://www.nexavar. com/ wt/page/index [Accessed 12 June 2006].
23. Escudier B, Szczylik C, Demkow T, et al. Randomized phase II trial of the multikinase inhibitor sorafenib versus interferon (IFN) in treatment-naïve patients with metastatic renal cell carcinoma (mRCC) [Abstract]. J Clin Oncol 2006; 24 (suppl):4501.
24. Gollob J, Richmond T, Jones J, et al. Phase II trial of sorafenib plus interferon-alpha 2b (IFN-α2b) as first- or second-line therapy in patients (pts) with metastatic renal cell cancer (RCC) [Abstract]. J Clin Oncol 2006; 24 (suppl):4538.
25. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6:491-500.
26. Robert C, Faivre S, Raymond E, et al. Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors? Ann Intern Med 2005; 143:313-314.
27. Strumberg D, Awada A, Hirte H, et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? Eur J Cancer 2006; 42:548-556.
28. Hood JD, Meininger J, Ziche M, et al. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998; 274 (3 Pt 2):H1054-H1058.
29. Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006; 24:1363-1369. An interesting study that examines potential mechanisms of hypertension in a series of patients receiving sorafenib.
30. Maitland M, Moshier K, Imperial J, et al. Blood pressure (BP) as a biomarker for sorafenib (S), an inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway [Abstract]. J Clin Oncol 2006; 24 (suppl):2035.
31. Lamuraglia M, Lassau N, Chami L, et al. Doppler ultrasonography with perfusion software and contrast agent injection as a tool for early evaluation of metastatic renal cancers treated with the Raf kinase and VEGFR inhibitor: a prospective study [Abstract]. J Clin Oncol 2005; 23 (suppl):3069.
32. Gatzemeier U, Blumenschein G, Fosella F, et al. Phase II trial of single-agent sorafenib in patients with advanced nonsmall cell lung carcinoma [Abstract]. J Clin Oncol 2006; 24 (suppl):7002.
33. Schiller JH, Flaherty KT, Redlinger M, et al. Sorafenib combined with carboplatin/ paclitaxel for advanced nonsmall cell lung cancer: A phase I subset analysis [Abstract]. J Clin Oncol 2006; 24 (suppl):7194.
34. Adjei A, Mandrekar S, Marks RS, et al. A phase I study of BAY43-9006 and gefitinib in patients with refractory or recurrent NSCLC. J Clin Oncol 2005; 23 (Suppl.):3067.
35. Dahut L, Scripture CD, Posadas EM, et al. Bony metastatic disease responses to sorafenib (BAY 43-9006) independent of PSA in patients with metastatic androgen independent prostate cancer [Abstract]. J Clin Oncol 2006; 24 (suppl):4506.
36. Steinbild S, Mross K, Morant D, et al. Phase II study of Sorafenib (BAY 43-9006) in hormone-refractory patients with prostate cancer: A study of the Central European Society for Anticancer Drug Research - EWIV (CESAR) [Abstract]. J Clin Oncol 2006; 24 (suppl):3094.